Medifast Q2 2026 Earnings Report

Medifast EPS Results

• Actual EPS: -$0.28
• Consensus EPS: -$0.65
• Beat/Miss: Beat by +$0.37
• One Year Ago EPS: N/A

Medifast Revenue Results

• Actual Revenue: $76.38 million
• Expected Revenue: $72.70 million
• Beat/Miss: Beat by +$3.68 million
• YoY Revenue Growth: N/A

Medifast Announcement Details

• Quarter: Q2 2026
• Date: 8/3/2026
• Time: After Market Closes
• Conference Call Date: Monday, August 3, 2026
• Conference Call Time: 4:30PM ET

Medifast (NYSE:MED), Inc. (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions. The company went public in 2001 and has since expanded its operations beyond the United States, serving customers in both the U.S. and Canada. Its offerings are distributed through a combination of e-commerce platforms and regional distribution centers, enabling efficient delivery of products to end users and reinforcing Medifast’s direct‐to‐consumer business model.

Under the leadership of President and Chief Executive Officer Daniel Chard, Medifast continues to invest in product innovation, digital tools and community building to strengthen customer engagement and retention. The company’s management team emphasizes evidence‐based program development and high standards of quality control, reflecting its commitment to clinical rigor and long‐term client success. With a focus on metabolic health and sustainable lifestyle transformation, Medifast aims to maintain its position as a leader in the weight‐management industry.

Medifast Q2 2026 Earnings Call Transcript

Key Takeaways

• Negative Sentiment: Revenue and coach counts continued to decline: Q2 revenue fell 27.6% year over year to $76.4 million, while active earning coaches dropped 48.7% to approximately 11,700, reflecting ongoing pressure from GLP-1 medication adoption. The company reported a $3.1 million net loss, or $0.28 per share, versus net income of $2.5 million a year earlier.
• Positive Sentiment: Coach productivity improved for a third consecutive quarter. Revenue per active earning coach increased 41% year over year and 20% sequentially to $6,529, the highest level since Q2 2022; management views this as an early indicator of eventual coach and revenue growth.
• Positive Sentiment: Medifast launched its new Trilivy metabolic-health brand, replacing OPTAVIA as its primary consumer brand, alongside new Reset Fuelings and the Medifast Metabolic Health Institute. Management said coach and client reception has been highly positive and expects the initiatives to support growth through the remainder of 2026.
• Positive Sentiment: Management is targeting a return to profitability in Q4 2026. The Catalyst cost-savings program, expected to ramp in Q3, is intended to generate millions of dollars in savings through facility rationalization, AI efficiencies, and other streamlining actions, although the company has not yet quantified the savings or implementation costs.
• Neutral Sentiment: Medifast ended Q2 with $169.8 million in cash and investments and no debt, but expects continued near-term coach-count declines. Q3 guidance calls for revenue of $60 million to $80 million and a loss of $0.15 to $0.65 per share, excluding one-time Catalyst costs; full-year revenue guidance remains $270 million to $300 million.

Presentation

[Operator]

Greetings, welcome to the Medifast second quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steven Zenker, Vice President, Investor Relations. Thank you, sir. You may begin.

[Steven Zenker, VP of Investor Relations at Medifast]

Good afternoon, welcome to Medifast's second quarter 2026 earnings conference call. On the call with me today are Nicholas Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer. By now, everyone should have access to the earnings release for the second quarter ended June 30th, 2026, that went out this afternoon at approximately 4:05 P.M. Eastern Time. If you have not received the release, it is available on the investor relations portion of Medifast's website at www.medifastinc.com. This call is being webcast, a replay will also be available on the company's website. Before we begin, we would like to remind everyone that today's prepared remarks contain forward-looking statements, management may make additional forward-looking statements in response to your questions. The words believe, expect, anticipate, other similar expressions generally identify forward-looking statements.

[Steven Zenker, VP of Investor Relations at Medifast]

These statements do not guarantee future performance, therefore, undue reliance should not be placed on them. Actual results could differ materially from those projected in any forward-looking statements. All of the forward-looking statements contained herein speak only as of the date of this call. Medifast assumes no obligation to update any forward-looking statements that may be made in today's release or call. Now, I would like to turn the call over to Medifast's Chief Executive Officer, Nicholas Johnson.

[Nicholas Johnson, CEO at Medifast]

Thanks, Steve, good afternoon, everyone. It's an honor to be addressing you today in my first earnings call as the Chief Executive Officer of Medifast, I'm looking forward to conversations with investors over the months and years ahead. In our second quarter, we continued to see positive indicators in our business, maintaining a trend that began in late 2025. Most notably, revenue has stabilized sequentially over the recent quarters, aided by higher coach productivity, which grew for the third consecutive quarter. This is a key metric for us, as positive trends historically have preceded revenue and profitability growth. Improved coach productivity is also reflected in the growing percentage of active earning coaches reaching executive director rank as our field embraces our strategic transition to metabolic health. We anticipate that these positive trends will continue through the remainder of the year, supported by the launch of our new consumer brand, Trilivy.

[Nicholas Johnson, CEO at Medifast]

Trilivy is the first step in our 3.0 strategy, which is the biggest shift for Medifast since we launched OPTAVIA in 2017. The strategy is defined by a 10-year roadmap that will allow us to expand our offer to coaches and clients in the context of a comprehensive metabolic health system while also broadening our geographic and demographic footprints. We have made substantial progress this year, launching a new brand, a new scientific institute, an enhanced coach compensation structure, and a standardized training system for our coaches. Each is a significant step forward, and together they help form a foundation for us to win in the metabolic health category. The way we are running the 3.0 organization centers around four core defining characteristics, namely speed, simplicity, scale, and stewardship.

[Nicholas Johnson, CEO at Medifast]

We have to move quickly to take advantage of the opportunity that exists in metabolic health while also returning the business to profitability. This speed imperative is reflected in the launch of a series of new initiatives that we will share more about on this call, but also in setting and maintaining a sustainable pace to our work and finding ways to do more with less. Simplicity is part of the narrative that underpins our business model and the ease with which we empower coaches to build their businesses. The less complexity our coaches face, the more they can focus on what actually grows their businesses. We have to eliminate what doesn't serve our coaches and clients and optimize the things that do. Scale matters because everything we are building is designed to compound.

[Nicholas Johnson, CEO at Medifast]

Each new coach and client fuels our flywheel, while stewardship underlines our commitment to building a business that is consistently profitable and that delivers for years to come. A key source of fuel for our flywheel is our new consumer brand, Trilivy, which succeeds OPTAVIA as our primary consumer brand. For years, the OPTAVIA brand was known primarily for one outcome, weight loss, which was just a single element of its effectiveness in helping people live a healthier lifestyle. Trilivy reflects the holistic health benefits our system is intended to deliver. A metabolic reset that helps the body work better over time through three distinct phases: reset, refine, and renew. Our science supports clients from end to end in a clear and compelling way that better aligns the brand with the daily realities of our coaches and clients today and into the future. We believe the opportunity is large.

[Nicholas Johnson, CEO at Medifast]

More than 90% of U.S. adults and 1.5 billion adults worldwide are metabolically unhealthy. Our study of more than 1,000 adults found nearly 94% are concerned about at least one aspect of their metabolic health. 85% believe metabolic dysfunction can be reversed, and 84% see it as central to overall wellbeing. 80% say they do not really understand what metabolic health means. There is high public concern, a belief that change is possible, but low understanding of how to do that. Our science-backed, coach-guided system closes that understanding gap. Attention on body composition, lean mass, and muscle preservation has never been higher as GLP-1 adoption and awareness continues to grow. Our comprehensive metabolic health system offers holistic lifestyle change and behavioral modification through the coaching and structured nutrition that is central to all of our plans.

[Nicholas Johnson, CEO at Medifast]

We continue to engage the GLP-1 market and beyond, supporting people throughout their health journey, whether they're using medication, coming off it, or pursuing metabolic health through non-medication pathways. Our coach-led program builds on more than 45 years of clinical and scientific heritage and is built around metabolic synchronization, our proprietary science that reverses metabolic dysfunction. Our clinically proven plans activate targeted fat burn while preserving lean mass. Our most popular plan reduces visceral fat by 14% while retaining 98% of lean mass over 16 weeks. In a clinical study, clients working with a coach lost up to 10x more weight and 17x more fat than those trying on their own. That is the structural advantage at the heart of our model. It sets us apart in a crowded market.

[Nicholas Johnson, CEO at Medifast]

In July, we launched the Medifast Metabolic Health Institute with a mission to advance metabolic health through rigorous research and credible evidence-based education. Led by recognized experts, including a dedicated scientific advisory board, and backed by teams with more than 390 years of collective professional experience. The institute organizes our work across research, product development, scientific communications, and education. It serves a clear commercial purpose: to strengthen the evidence base behind our programs, continue to substantiate an expanding set of health claims, and establish Medifast as a trusted authority in a field that most of the market is only beginning to understand. We expect that this is how we turn our scientific heritage into a durable, competitive advantage. We continue to build on our clinically proven science utilizing our MetaVantage Technology platform with the upcoming launch of our new Reset Fuelings.

[Nicholas Johnson, CEO at Medifast]

Each Fueling, like those in our previous Fuelings line, is nutrient-dense and pre-portioned with high-quality protein, fiber, probiotics, and more than two dozen vitamins and minerals. Added to the new product line are three key ingredients intended to make our products even more effective. This proprietary MetaVantage Technology Reset Formula is designed to unlock key metabolic pathways to help support normal fat metabolism, healthy insulin function, and reduced waist circumference. The new Fuelings anchor our clinically proven Reset 5 & 1 Plan, which activates a targeted fat burn to improve body composition, reducing visceral fat while retaining lean mass. This is our first product line designed to fully utilize our MetaVantage Technology Reset Formula. It strengthens our overall market differentiation. We ran a pilot this spring with certain employees, coaches, and clients. The feedback was overwhelmingly positive.

[Nicholas Johnson, CEO at Medifast]

We look forward to putting these products into the hands of all clients and coaches later this month. In the field, engagement is high, and that's showing in the metrics. Although the number of coaches continues to decline, active earning coach productivity was positive for the third straight quarter, with year-over-year productivity up 41% and sequentially up 20% versus our first quarter. Revenue per active earning coach is now the highest it has been since the second quarter of 2022. We expect the trend to continue through 2026. On August 1st, we launched an enhanced compensation plan that significantly sharpens our focus on developing and duplicating executive directors. As high-producing coaches, executive directors are the single greatest driver of sustainable growth for our business.

[Nicholas Johnson, CEO at Medifast]

The design of our new compensation plan was heavily informed by the success of our Edge program, which confirmed our belief that focusing our field on building Executive Directors empowers stronger leadership development and healthier field performance. The momentum we are seeing today reflects those Edge results. With the percentage of active earning coaches at the Executive Director rank or above continuing to climb, remaining over our 10% benchmark for a healthy, scalable field organization. This is a big area of focus for us as we move forward, and we believe our enhanced compensation plan builds on this proven foundation and will further accelerate growth over time. Our client referral program continues to exceed expectations, which is important as we launch the new product line and seek to capitalize on the enthusiasm and energy of the coaches as they lean into the new metabolic health narrative with clients.

[Nicholas Johnson, CEO at Medifast]

The renewed energy and excitement from the coach base was on display at our sold-out coach convention in July and was a clear indicator of the strength of coach engagement right now. We used the opportunity to focus coach attention on key initiatives, including Trilivy's new products, the simplified compensation plan, and our new coach-developed Trilivy CoachHub training platform. Simplifying the fundamentals of our products and programs, but also the way we talk about them, is a critical component of our collective commitment to bringing the company back to profitability and improving the scalability of our business. The energy at the conference was remarkable, and it's encouraging to see a new generation of coaches engaging with the new brand and the enhanced approach to metabolic health as we seek to reset, refine, and renew lives.

[Nicholas Johnson, CEO at Medifast]

Before I turn it over to Jim for a detailed look at the financials, I want to touch on a few key data points. We met expectations for the quarter on both revenue and earnings. Second quarter revenue was $76 million, in line with the guidance we provided in May. The results reflect higher coach productivity and improved client retention trends and is consistent with a business whose operating indicators are starting to turn more positive. Our balance sheet remains a source of strength. We ended the quarter with more than $169 million in cash and investments and no debt. Our enterprise value today sits below the value of our cash and investments. The restructuring actions of the past two years reduced our cost base significantly while preserving the capabilities we need to grow.

[Nicholas Johnson, CEO at Medifast]

During Q2, we launched our Catalyst program, with the majority of the execution expected to take place in Q3. The Catalyst program is designed to drive additional cost savings through facility rationalization, AI-related efficiencies, and other means, all while being certain we do not negatively impact our ability to grow. By intensifying our focus on improving profitability, we believe we will be in a stronger financial position to execute our 10-year growth strategy successfully. Our near-term focus is straightforward. We aim to return to profitability by the fourth quarter of 2026. We are executing on both sides of the equation, enhancing initiatives to grow revenue and eliminating cost across the business, and we believe we are on track to deliver it. All of this comes back to my earlier comments about running this organization on the key tenets of speed, simplicity, scale, and stewardship.

[Nicholas Johnson, CEO at Medifast]

We are moving fast without overreaching, simplifying how our coaches build their businesses, and building a model designed to strengthen as the field grows. We have a clear long-term plan built around helping clients achieve optimal metabolic health. It is backed by breakthrough science and delivered through a coach-led model that we believe is a real structural advantage. We are already seeing progress in key areas of our business, ahead of the impact of the new brand, products, and training. We have the science, the brand, the products, and the coaches to compete and win in metabolic health, and we have the financial strength to create a platform for growth. There is more to be done, but we have entered the second half of the year with a clear focus on fulfilling both our short and long-term business objectives.

[Nicholas Johnson, CEO at Medifast]

With that, I'll hand over to Jim to run through the financials.

[Jim Maloney, CFO at Medifast]

Thank you, Nicholas. Good afternoon, everyone. Second quarter 2026 revenue was within our guidance range, and second quarter EPS exceeded our guidance range, supported by a third consecutive quarter of year-over-year coach productivity growth. Revenue for the second quarter was $76.4 million, a decrease of 27.6% versus the year earlier period, primarily due to a decrease in the number of active earning coaches. We ended the quarter with approximately 11,700 active earning coaches, a decrease of 48.7% from the second quarter of 2025. The company continues to see an impact from the rapid adoption of GLP-1 medication across the traditional weight-loss category, which is contributing to this decline. In response, we continued our work on building a new coach leadership structure, which includes deprioritizing less productive coaches and developing a network of the most productive executive director organizations.

[Jim Maloney, CFO at Medifast]

This work resulted in average revenue per active earning coach for the second quarter of $6,529, a year-over-year increase of 41.0%. We now have a clear trend of increasing coach productivity both year-over-year and sequentially. We continue to believe that increases in revenue per active earning coach are an early indicator for future coach growth, which we believe will in turn lead to revenue growth. Gross profit for Q2 2026 decreased 30.3% year-over-year to $53.4 million, driven by lower sales volumes. Gross profit margin for the current quarter was 69.9%, compared to 72.6% for the second quarter of 2025, primarily driven by the loss of leverage on fixed costs.

[Jim Maloney, CFO at Medifast]

SG&A expense was down 25.7% year-over-year to $57.7 million, primarily due to a $12.6 million decrease in coach compensation on lower volume and fewer active earning coaches, a $2.3 million decrease in employee salary and benefit expenses, and a $2 million decrease in company-led marketing costs. SG&A as a percentage of revenue increased 200 basis points, primarily due to approximately 290 basis points associated to loss of leverage on fixed costs and 60 basis points associated with the launch of the company's new Trilivy Reset product line, partially offset by a 190 basis point reduction related to company-led marketing costs. As Nicholas mentioned earlier, we launched our Catalyst program during Q2 and will have more to share about these cost savings and streamlining initiatives as they ramp up in Q3.

[Jim Maloney, CFO at Medifast]

We continue to include in our guidance the belief that improvements to get back to profitability will start in Q4 2026, and the Catalyst program will be a large part of how we accomplish that objective. Loss from operations was $4.3 million in the second quarter of 2026, an increase in losses of $3.3 million versus the year earlier period, as the decline in gross profit was largely offset by lower SG&A. As a percentage of revenue, loss from operations was 5.7% in the second quarter, a 470 basis points change from 1.0% in the year earlier comparable period. Other income decreased $2.6 million year-over-year to $1.3 million, primarily due to gains on our investment in LifeMD common stock in the year earlier period. As a reminder, we sold our common stock investment in LifeMD during the second quarter of 2025.

[Jim Maloney, CFO at Medifast]

Income tax expense for the period was $0.1 million, an effective rate of negative 3.6%, as compared to $0.4 million for the second quarter of 2025, an effective rate of 13.7%. Due to the existence of a full valuation allowance against its deferred tax assets recorded as of December 31, 2025, the company calculated income tax expense for the current period based on actual results for the quarter. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the June 30, 2026 period and the valuation allowance on the net deferred tax assets. Net loss in the second quarter of 2026 was $3.1 million, or $0.28 per diluted share, compared to a net income of $2.5 million, or $0.22 per share in the year earlier period.

[Jim Maloney, CFO at Medifast]

With respect to our balance sheet, we ended the year with $169.8 million in cash equivalents, and investments, and no debt as of June 30, 2026. Additionally, our working capital, defined as current assets less current liabilities, was $160.5 million as of December 31, 2025. Now I'll turn to guidance. We're expecting third quarter revenue to range from $60 million-$80 million, and loss per share for the quarter to range from $0.15-$0.65. This excludes any one-time costs associated with the execution of our Catalyst initiatives. While we expect to continue to see the active earning coach count to decline in the short term, we expect to see continued coach productivity growth during the quarter, up both year-over-year and sequentially.

[Jim Maloney, CFO at Medifast]

For the full year 2026, we expect revenue to range from $270 million-$300 million, and loss per share between $0.25-$1.75. We continue to include in our guidance the belief that improvements to get back to profitability will start in Q4 2026, following the launch of our new product line, and we will be targeting improvements in earnings to continue into 2027 and beyond. Finally, we believe that our working capital will be more than $145 million at December 31st, 2026. With that, let me turn the call back to the operator for questions.

[Operator]

Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question comes from Jim Salera with Stephens Inc. Please proceed with your question.

[Jim Salera, Equity Research Analyst at Stephens]

Guys, good afternoon. Thanks for taking our question. We wanted to start out with some questions around the Catalyst program. I think investors will be encouraged to hear visibility towards profitability in 4Q of 2026. Would love some more detail around, I guess, the initial implementation costs of the Catalyst program, the expected savings, and maybe the cadence of when we should start to see the costs flow through the P&L versus the realization of the savings.

[Jim Maloney, CFO at Medifast]

Jim, we were very intentional in our prepared remarks to say that there's going to be more to come on the Catalyst program and its savings. What we can say now is we believe there's millions of savings, millions of dollars of savings, but we're not able to quantify it because we're actually working through what we plan to reduce. The focus of Catalyst is to take and simplify the business, but not take costs out that will impact top-line revenues. We're still continuing to do certain investments within the top line that we believe will help that, and we're continuing to focus on executive directors, but we're not able to give the exact quantifications at this point. We are going to be doing that in our Q3 earnings call.

[Jim Salera, Equity Research Analyst at Stephens]

Okay. If we think about the path to profitability or return to profitability in 4Q, is the Catalyst program the only lever there, or are there some other incremental contributors, whether it be top-line recovery, the new product launch? I don't know if there's any sort of margin change there. Anything that you could help give us the building blocks for that 4Q.

[Jim Maloney, CFO at Medifast]

Yeah, we kept our guidance on the top line the same versus last quarter. You're seeing that the last three quarters, Q4 of 2025, was approximately $75 million in revenue. Q1 and Q2 was also approximately $75 million revenue, we're targeting anywhere in the range of the guidance range that we gave of $60 million-$80 million this upcoming quarter. When you do the math at the midpoint, say we get to $70 million in revenue in Q3, at the midpoint, we'll have to get close to that number again in Q4 to be at the midpoint of the range. That gives you a feel of the top line, we didn't change the top line at all. We're feeling more and more confident in that top line. The EPS range that we're providing has actually gotten better.

[Jim Maloney, CFO at Medifast]

When you look at the full-year range of what we provided last quarter versus this quarter, even though we are excluding certain one-time charges, which we'll call out in our Q3 earnings call, what those were. Q4, when you do the math, you'll see how it gets better.

[Jim Salera, Equity Research Analyst at Stephens]

Okay. Maybe one more from me. With the launch of the revamped product offering in Trilivy, can you just walk us through the coach receptivity to that, how the transition, moving people over from the old OPTAVIA system to the new system is going, any hiccups or bumps we should think about there, then I guess once we're kind of fully switched over, maybe some of the incremental opportunities that provides versus the old platforms?

[Nicholas Johnson, CEO at Medifast]

Thanks, Jim. I'll take the first part of the question, which is around the receptivity across the field, and then with respect to the specifics of the rollout margin, anything of that nature, I'll turn it over to our Jim to go over those. From a receptivity perspective, we saw a tremendous amount of positive reception to the change, notably around our ability to develop a metabolic health platform, which goes beyond what we've traditionally been known for inside of the OPTAVIA brand as weight loss. So number one, an expanded opportunity rooted in metabolic health. Two, we launched a series of initiatives in addition to the new brand, and what we're seeing so far with respect to the coach pre-launch of the new Trilivy Fuelings has been very positive. We've seen a lot of activity in that space so far.

[Nicholas Johnson, CEO at Medifast]

From the sold-out event at our convention a few weeks ago to the uptake of the coach pre-launch, we're seeing that as a good signal of receptivity of the change. We've seen no major hiccups with respect to that change and the evolution of the brand. Instead, we've seen a lot of positivity from our field with respect to the renewed opportunity inside of metabolic health. We do have a plan to roll out those fuelings across the next quarters. I'll have Jim comment on what that's looking like in addition to any sort of improvement on the margin side.

[Jim Maloney, CFO at Medifast]

Overall, speaking to 2026, stabilization of our top line will help our margins. With the impact of what we did in past quarters and moving into Catalyst, that should help with margins. As we move from a loss in Q2 and we move into focusing on Q4, we do expect better overall margins to our business. Then think about 2027. We are saying that we're focusing on profitability in 2027 also. When you think about the last several quarters, what we've talked about, the majority of our margin loss has been due to the loss of leverage of the decline. As the business stabilizes into 2027 and beyond and starts to grow, that loss of leverage actually starts to become a positive.

[Jim Maloney, CFO at Medifast]

As we mentioned in our prepared remarks, this increase in productivity per coach in our past history, that has led to coach growth, which then has led to revenue growth. We are expecting that to reoccur. Obviously, we're in a different world with GLP-1 medications, but there's nothing, at least at this point, telling us anything differently that we should expect at some point that coach growth will happen, and we'll start picking up the leverage points of our fixed cost as the business grows in the out periods.

[Jim Salera, Equity Research Analyst at Stephens]

Great. I appreciate the thoughts. I'll pass it on.

[Operator]

We have reached the end of our question and answer session. I would now like to turn the floor back over to Nicholas Johnson for closing comments.

[Nicholas Johnson, CEO at Medifast]

Thank you everyone for joining us today and for your continued interest in Medifast. As we move through the second half of 2026, our focus remains steadfast on executing our 3.0 strategy and driving the successful rollout of the Trilivy brand. We're energized by the positive momentum in coach productivity and engagement and are confident that the foundational work we are doing today, centering on speed, simplicity, scale, and stewardship, is setting the stage for a return to profitability in the fourth quarter. We look forward to updating you on our progress during our next call. Have a great afternoon.

[Operator]

This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.

Participants

Executives

• Steven Zenker, VP of Investor Relations
• Nicholas Johnson, CEO
• Jim Maloney, CFO

Analysts

• Jim Salera, Equity Research Analyst at Stephens